SSgA SPDR MSCI ACWI ex-US
Latest SSgA SPDR MSCI ACWI ex-US News and Updates
Using Asian Markets’ Low Correlation with US Markets
The correlation between US and international markets varies depending on market cycles.
Allergan Generics Has Strengthened Teva’s Research Pipeline
The acquisition of Allergan’s (AGN) generic business has helped Teva’s R&D pipeline become the strongest generic drug pipeline in the world.
Teva Is Well Placed to Dominate the European Generics Market
Teva is in the first three positions in 26 countries in the European Union. The Teva–Allergan Generics deal helped Teva expand.
Teva’s Generic Value Chain Differentiates It from Its Peers
In addition to its robust strategy, Teva Pharmaceutical also boasts of an extensive presence across all levels of the value chain for its generics business.
Teva Pharmaceutical Expected to See Strong Revenue Growth in 2016
In 2016, Teva Pharmaceutical (TEVA) expects to earn revenues of $22.0 billion–$22.5 billion. This includes contribution from sales of Allergan Generics products.
Teva Aims to Improve Its Position with Actavis Generics Acquisition
Teva Pharmaceutical expects to benefit from improved productivity after the completion of the deal with Actavis Generics.
Bendeka: How Teva Plans to Safeguard Oncology Revenues
In the first quarter of 2016, Teva Pharmaceutical Industries (TEVA) launched a new drug, Bendeka, in partnership with Eagle Pharmaceuticals.
